BMRN Stock Recent News
BMRN LATEST HEADLINES
BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Alexander Hardy - President, CEO & Director Brian R. Mueller - Executive VP of Finance & CFO Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Traci McCarty - Group Vice President Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Alexandria Janet Hammond - Wolfe Research, LLC Allison Marie Bratzel - Piper Sandler & Co., Research Division Cory William Kasimov - Evercore ISI Institutional Equities, Research Division Ellen Horste - TD Cowen, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jasmine Alexandra Fels - UBS Investment Bank, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Konstantinos Biliouris - BMO Capital Markets Equity Research Olivia Simone Brayer - Cantor Fitzgerald & Co., Research Division Paul
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $0.96 per share a year ago.
Second Quarter 2025 Total Revenues of $825 million (+16% Y/Y and +17% at Constant Currency Y/Y) Second Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $1.23 (+124% Y/Y) Second Quarter 2025 Non-GAAP Diluted EPS of $1.44 (+50% Y/Y) BioMarin Completes Acquisition of Inozyme in July 2025; Pivotal Data from Lead Indication Expected 1H'26 BMN 333 Exceeds Targeted Exposures of Free C-type Natriuretic Peptide (CNP) in Healthy Volunteer Study; Pivotal Phase 2/3 Study with BMN 333 in Pediatric Achondroplasia Planned to Begin 1H'26 Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.
SAN RAFAEL, Calif. , Aug. 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Ian T.
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN RAFAEL, Calif. , July 22, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 4, 2025, at 4:30 p.m.
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.